|
[1-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(4-acetamidophenyl)-1,3-dioxoisoindole-5-carboxylate |
|
Burkholderia Yersinia |
Bsa T3SS TTSS (Type III secretion system) |
Preclinical (in vitro) Preclinical (in vivo) |
Swietnicki W, et al. 2011. PLoS One
|
|
3-(6,6-dimethyl-3-oxotetrahydro-2H-pyran-2-yl)-3-hydroxy-1,3-dihydro-2H-indol-2-one |
Depiction based on curated SMILES
O
N
H
O
CH
3
OH
O
CH
3
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
von Ambüren J, et al. 2020. Microorganisms |
|
3-hydroxy-3-[2-oxo-2-(pyridin-4-yl)ethyl]-1,3-dihydro-2H-indol-2-one |
Depiction based on curated SMILES
OH
N
O
HN
O
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
von Ambüren J, et al. 2020. Microorganisms |
|
4-[1,3-dioxo-5-(4-oxo-4H-3,1-benzoxazin-2-yl)-1,3-dihydro-2H-isoindol-2-yl]benzoic acid |
Depiction based on curated SMILES
OH
O
O
N
O
N
O
O
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |